STAT3 and neoplasm: Preclinical studies strongly suggest significant efficacy of drugs targeting GP130/JAK/STAT3 in the treatment of PDAC and that these molecules are effective chemosensitizers, possibly through simultaneous effect on tumor cells and TME.